OUT COMES AFTER CAR T CELL THERAPY IN THE LONG RUN

Samaa Faez

doi:10.61796/jmgcb.v2i5.1297

Authors

Samaa Faez
samaa.faiz12@gmail.com
University of Thi-Qar, Iraq

Vol. 2 No. 5 (2025): Journal of Medical Genetics and Clinical Biology

Articles

May 16, 2025

Downloads

VIEW ARTICLE

Abstract
How to Cite
Metrics
References
License

Objective: During the past several years, there has been a lot of discussion regarding the utilization of chimeric antigen receptor T-cells as an immunotherapy treatment for malignancies. Method: The scope of this study encompasses not only the negative consequences that CAR-T cells have, but also the mechanisms that are responsible for those effects, as well as potential treatments. Results: Through the utilization of this therapy strategy, both hematological malignancies and solid tumors have been successfully treated. However, it has been associated with a number of adverse reactions, such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), off-target effects, anaphylaxis, infections associated with CAR-T cell infusion (CTI), tumor lysis syndrome (TLS), B-cell dysplasia, hemophagocytic lympho histiocytosis (HLH)/macrophage activation syndrome (MAS), and coagulation disorders. Novelty: The therapeutic application of CAR-T cell therapy can be informed by this evaluation, which will furnish critical reference data.

M. Kalos and C. H. June, "Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology," Immunity, vol. 39, no. 1, pp. 49–60, Jul. 2013, doi: 10.1016/j.immuni.2013.07.002.

M. Sadelain, R. Brentjens, and I. Rivière, "The basic principles of chimeric antigen receptor design," Cancer Discovery, vol. 3, no. 4, pp. 388–398, Apr. 2013, doi: 10.1158/2159-8290.cd-12-0548.

K. M. Cappell et al., "Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy," Journal of Clinical Oncology, vol. 38, pp. 3805–3815, 2020.

F. L. Locke et al., "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma," New England Journal of Medicine, vol. 386, pp. 640–654, 2022.

E. A. Chong, M. Ruella, and S. J. Schuster, "Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy," New England Journal of Medicine, vol. 384, pp. 673–674, 2021.

T. Siddiqi et al., "Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL," Blood, vol. 139, pp. 1794–1806, 2022.

E. C. Morris, S. S. Neelapu, T. Giavridis, and M. Sadelain, "Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy," Nature Reviews Immunology, vol. 22, no. 2, pp. 85–96, 2022.

S. S. Neelapu et al., "Chimeric antigen receptor T-cell therapy–assessment and management of toxicities," Nature Reviews Clinical Oncology, vol. 15, no. 1, pp. 47–62, 2018.

T. Badar, B. D. Johnson, and M. Hamadani, "Delayed neurotoxicity after axi-cabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma," Bone Marrow Transplantation, vol. 56, no. 3, pp. 683–685, 2021.

S. Jung, J. Greiner, S. von Harsdorf et al., "Fatal late-onset CAR T-cell mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma," Blood Advances, vol. 5, no. 19, pp. 3789–3793, 2021.

U.S. Food and Drug Administration (FDA), "Highlights of prescribing information: Yescarta," 2022. [Online]. Available: https://www.fda.gov/media/108377/download.

O. Obaisi, R. C. Fontillas, K. Patel, and A. Ngo-Huang, "Rehabilitation needs for patients undergoing CAR T-cell therapy," Current Oncology Reports, vol. 24, no. 6, pp. 741–749, 2022.

R. J. Lin et al., "Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older lymphoma patients," Blood Advances, vol. 7, pp. 3501–3505, 2023.

I. Roy et al., "Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma," British Journal of Haematology, vol. 197, no. 1, pp. 71–75, 2022.

S. J. Grant et al., "Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review," Transplantation and Cellular Therapy, vol. 28, no. 6, pp. 294–302, 2022.

A. I. Hoogland, A. Barata, J. Logue et al., "Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy," Transplantation and Cellular Therapy, vol. 28, no. 6, pp. 305.e1–305.e9, 2022.

A. Cordeiro et al., "Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells," Biology of Blood and Marrow Transplantation, vol. 26, no. 1, pp. 26–33, 2020.

J. Ruark et al., "Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy," Biology of Blood and Marrow Transplantation, vol. 26, no. 1, pp. 34–43, 2020.

A. Barata, A. I. Hoogland, A. Kommalapati et al., "Change in patients' perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma," Transplantation and Cellular Therapy, vol. 28, no. 7, pp. 401.e1–401.e7, 2022.

M. S. Topp et al., "Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma," British Journal of Haematology, vol. 195, no. 3, pp. 388–398, 2021.

O. O. Oluwole et al., "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma," British Journal of Haematology, vol. 194, no. 4, pp. 690–700, 2021.

K. Rejeski et al., "The CAR-HEMATOTOX risk stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL," Journal for Immunotherapy of Cancer, vol. 10, no. 5, p. e004475, 2022.

W. A. Bethge, P. Martus, M. Schmitt, et al., "GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany," Blood, vol. 140, no. 4, pp. 349-358, 2022.

J. Lemoine, E. Bachy, G. Cartron, et al., "Causes and risk factors of early and late non-relapse mortality after CD19 CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL): a Lysa study from the Descar-T registry," Blood, vol. 140, pp. 1859-1861, 2022.

J. A. Hill and S. K. Seo, "How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies," Blood, vol. 136, no. 8, pp. 925-935, 2020.

T. W. Laetsch, S. L. Maude, S. Rives, et al., "Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial," J. Clin. Oncol., vol. 41, no. 9, pp. 1664-1669, 2023.

F. L. Locke, A. Ghobadi, C. A. Jacobson, et al., "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial," Lancet Oncol., vol. 20, no. 1, pp. 31-42, 2019.

J. N. Brudno and J. N. Kochenderfer, "Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management," Blood Rev., vol. 34, pp. 45-55, 2019.

J. N. Brudno and J. N. Kochenderfer, "Toxicities of chimeric antigen receptor T cells: recognition and management," Blood, vol. 127, pp. 3321-3330, 2016.

F. L. Locke, et al., "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial," Lancet Oncol., vol. 20, pp. 31-42, 2019.

J. M. Logue, et al., "Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma," Haematologica, vol. 106, pp. 978-986, 2021.

A. Cordeiro, et al., "Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells," Biol. Blood Marrow Transpl., vol. 26, pp. 26-33, 2020.

T. Martin, et al., "Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up," J. Clin. Oncol., vol. 41, pp. 1265-1274, 2023.

N. C. Munshi, et al., "Idecabtagene vicleucel in relapsed and refractory multiple myeloma," N. Engl. J. Med., vol. 384, pp. 705-716, 2021.

J. N. Brudno, et al., "Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms," Leuk. Lymphoma, vol. 63, pp. 1849-1860, 2022.

S. Fried, et al., "Early and late hematologic toxicity following CD19 CAR-T cells," Bone Marrow Transpl., vol. 54, pp. 1643-1650, 2019.

K. S. Hanna, H. Kaur, M. S. Alazzeh, et al., "Cardiotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies: a systematic review," Cureus, vol. 14, no. 8, p. e28162, 2022.

H. Liu, Y. Ma, C. Yang, et al., "Severe delayed pulmonary toxicity following PD-L1-specific CAR T-cell therapy for non-small cell lung cancer," Clin Transl Immunology, vol. 9, no. 10, p. e1154, 2020.

R. Chakraborty, B. T. Hill, A. Majeed, and N. S. Majhail, "Late effects after chimeric antigen receptor T-cell therapy for lymphoid malignancies," Transplant Cell Ther., vol. 27, no. 3, pp. 222-229, 2021

E. M. Holland, B. Yates, A. Ling, et al., "Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy," Blood Adv., vol. 6, no. 7, pp. 2167-2182, 2022.

S. Khanna, A. G. Mackin, D. T. Dao, et al., "Exudative retinal detachment following chimeric antigen receptor T-cell therapy in relapsed B-cell acute lymphoblastic leukemia," Ophthalmic Surg Lasers Imaging Retina, vol. 53, no. 2, pp. 113-115, 2022.

A. A. Mumtaz, A. Fischer, F. Lutfi, et al., "Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review," Br. J. Ophthalmol., vol. 107, no. 7, pp. 901-905, 2023.

J. Mahdi, J. Dietrich, K. Straathof, et al., "Tumor inflammation-associated neurotoxicity," Nat. Med., vol. 29, no. 4, pp. 803-810, 2023.

H. Shalabi, J. Gust, A. Taraseviciute, et al., "Beyond the storm: subacute toxicities and late effects in children receiving CAR T cells," Nat. Rev. Clin. Oncol., vol. 18, no. 6, pp. 363-378, 2021.

R. L. Mulder, A. Font-Gonzalez, D. M. Green, et al., "Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group," Lancet Oncol., vol. 22, no. 2, pp. e57-e67, 2021, doi: 10.1016/S1470-2045(20)30582-9.

R. L. Mulder, A. Font-Gonzalez, M. M. Hudson, et al., "Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group," Lancet Oncol., vol. 22, pp. e45-e56, 2021, doi: 10.1016/S1470-2045(20)30594-5.

T. Zver, S. Frontczak, C. Poirot, et al., "Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients," J. Ovarian Res., vol. 15, no. 1, p. 9, 2022, doi: 10.1186/s13048-021-00936-4.

J. A. Ligon, A. Fry, J. Y. Maher, et al., "Fertility and CAR T cells: current practice and future directions," Transplant Cell Ther., vol. 28, no. 9, pp. 605.e1-605.e8, 2022.

A. Deya-Martinez, A. Alonso-Saladrigues, A. P. Garcia, et al., "Kinetics of humoral deficiency in CAR T-19 treated children and young adults with acute lymphoblastic leukemia," Bone Marrow Transplant., vol. 56, no. 2, pp. 376-386, 2021.

E. Kampouri, C. S. Walti, J. Gauthier, and J. A. Hill, "Managing hypogammaglobulinemia in patients treated with CAR T-cell therapy: Key points for clinicians," Expert Rev. Hematol., vol. 15, no. 4, pp. 305-320, 2022.

J. A. Hill, E. M. Krantz, K. A. Hay, et al., "Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy," Blood Adv., vol. 3, no. 22, pp. 3590-3601, 2019.

K. Wudhikarn and M. A. Perales, "Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy," Bone Marrow Transplant., vol. 57, no. 10, pp. 1477-1488, 2022.

J. A. Hill and S. K. Seo, "How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies," Blood, vol. 136, no. 8, pp. 925-935, 2020.

B. D. Santomasso, L. J. Nastoupil, S. Adkins, et al., "Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline," J. Clin. Oncol., vol. 39, no. 35, pp. 3978-3992, 2021.